The campaign against the most valuable medical technologies ever invented is based on junk science.
Crucial improvements for women are a routine byproduct of the search for new profits by international firms.
Anyone who thinks the vaccine case now before the Supreme Court is merely a matter of giving injured plaintiffs their day in court has misconceived the stakes for those who reap the benefits of vaccines.
President Obama made BP’s problem worse, and in so doing has worsened the problems facing not only the administration but also the unfortunate residents of the Gulf of Mexico.
The Rand Paul episode reveals a drastic misreading of history and of the government’s role in ending racial discrimination in this nation.
Instead of trying to figure out how to make prices in healthcare markets transparent, as a Democratic bill aims to do, let the market decide.
Medical breakthroughs from using existing drugs in new ways await discovery—if manufacturers have an incentive to pursue them.
As with the run-up to the Senate healthcare bill, we are again paying the cost of haste. Far too little attention is being given to crucial matters.
The healthcare overhaul is shaping up as the highest-risk legislation in modern times.
There is a second world of drug research, a world in which patents do not exist and for-profit research is permanently moribund. Its history should stop ‘reformers’ in their tracks.
Congress is poised to pass one of the worst public health laws ever conceived.
In good news, the U.S. Patent and Trademark Office has resisted researchers' overreaching in their patenting of genes, and researchers’ work is seldom compromised by patents.
The Supreme Court’s decision in Wyeth v. Levine will be negative for patient welfare.
Maurice Hilleman's remarkable period of industrial scientific research yielded the most cost-effective medicines ever made.
Obama’s FDA commissioner should avoid actions that make the drug development process more costly and inefficient.
Marketing-driven clinical trials intend to increase sales and profits—but also yield enormous benefits for patients.
New efforts to undermine the country’s drug development system are cause for worry.
A surprising new study on heart disease treatments won’t just change medicine—it will help shape basic science.
Many people love to hate DTCA, but research suggests the ads do more good than harm.